ERBB2 and breast carcinoma: Evidence suggests that in breast cancer cells, including that of metastatic breast tissues, HER2 physically interacts with CB2, forming a heterodimeric complex and is correlated to a poor patient prognosis; this corresponds with the fact that 91% of HER2 positive breast tumours also show CB2 expression in immunohistochemical analysis (21, 120).